A new biologics production architecture.
The Challenge
Animal agriculture faces mounting structural constraints.
- Antibiotic use is being phased down globally, increasing demand for functional biological alternatives.
- Synthetic pigments provide colour but lack biological efficacy.
- High-efficacy biologics remain restricted by sterile cell culture, petrochemical synthesis, or energy-intensive production routes.
Existing production approaches have both high cost and scaling challenges:
- Sterile cell culture (proteins)
- Petrochemical synthesis (synthetic astaxanthin)
- Energy-intensive algal systems (natural carotenoids)
FlyPharma addresses these constraints with a genetically engineered insect expression platform designed for industrial deployment.
Breakthrough Platform
FlyPharma targets high-volume, multi-billion-dollar animal health markets.
FlyPharma is pioneering a new biological production architecture which uses genetically modified Black Soldier Fly strains as in vivo expression hosts.
Biologics are expressed during larval growth and concentrated in harvestable biomass.
- Integrated genetics and automation
- Modular industrial deployment
- Designed for feed-grade economics
Breakthrough costs of production:
- Eliminates sterile bioreactors
- Dramatically reduces capital intensity
- Enables short biological production cycles
- Designed for modular deployment
Industrial Control & Automation
FlyPharma’s platform couples genetic engineering with automated production systems to ensure consistent, high-volume output.
The platform is designed to deliver consistent output at industrial scale:
Automated rearing and environmental control systems reduce variability
Standardised process architecture enables repeatable scale-up
Integrated sensor networks monitor performance in real time
Continuous data feedback drives yield optimisation across production cycle
This closed-loop system transforms biological production into an engineered manufacturing process — delivering dependable supply at industrial scale.
Feed Grade Economics - Industrial Volumes
By embedding molecular expression directly within biological growth and automating production end-to-end, FlyPharma shifts cost structures fundamentally.
- Reduced capital intensity
- Low-cost biological inputs
- Short biological production cycles
- Designed for high-volume deployment
Biologics move from specialty input to scalable baseline component.
Platform Progress
Advancing an integrated biologics production architecture.
Execution underway across genetics, automation, and regulatory development.
Genetics
Exclusive GM strain agreement executed.
Expression platform secured.
Automation
Integrated production systems operational at Brisbane pilot facility.
Industrial process architecture validated in live deployment.
Regulatory
Regulatory engagement initiated.
Process development and commercial pathway advancing in parallel.
Commercial validation discussions underway with leading swine, poultry producers and strategic partners.
End Markets
Biologics already proven to work; cost structure has prevented adoption. FlyPharma changes that.
Designed for global, distributed deployment.
Poultry
Problem: Poultry producers need reliable ways to protect gut health while reducing antibiotic use.
Solution: Biologics can help, but cost has limited everyday use.
FlyPharma makes low-cost biologics suitable for routine feed inclusion.
Swine
Problem: Swine operations face ongoing disease pressure and productivity loss linked to gut health. Current biologic options are difficult to scale and price consistently.
Solution: FlyPharma enables biologics designed for continuous, large-scale feed programs.
Aquaculture
Problem: Fish and shrimp farming are under growing pressure from disease, regulation, and antibiotic limits. Most biologics fail to meet volume and cost needs.
Solution: FlyPharma supports biologics that fit commercial aquafeed systems.
Feed Additives & Pigments
Problem: Synthetic feed additives and colour pigments face rising cost and regulatory pressure. Natural alternatives exist but are hard to produce at scale.
Solution: FlyPharma enables biological additives and pigments at industrial volumes.
Engineered Expression
FlyPharma’s platform is grounded in advanced genetic engineering and applied entomology.
Biological Rationale
Genetically modified Black Soldier Fly strains function as in vivo expression hosts, enabling production of targeted proteins and bioactive compounds during growth.
Designed for Industrial scale
Process control and yield optimisation are integrated into industrial production systems.
About FlyPharma
FlyPharma is headquartered in Australia with platform operations underway in Brisbane.
Founded by Constant Tedder, serial entrepreneur with three prior exits, FlyPharma is building a biologics production architecture designed for industrial deployment.
FlyPharma’s platform integrates genetic engineering, automated production systems, and process control to enable scalable, feed-grade manufacturing.
What We Do
We develop and operate an integrated insect expression platform capable of producing bioactive proteins and natural pigments at high volume.
The system is engineered for consistent output, controlled cost structures, and commercial-scale supply.
How We Work
FlyPharma operates as a manufacturing platform company.
We focus on systems, repeatability, and long-term deployment — supporting sustained commercial production rather than short-term experimental output.
Contact
FlyPharma operates as a manufacturing platform company.
We focus on systems, repeatability, and long-term deployment — supporting sustained commercial production rather than short-term experimental output.
Contact
We welcome enquiries related to partnerships, commercial discussions, and research collaboration.